Following an inspection conducted in September 2023, the U.S. FDA found quality control issues at Moderna’s primary manufacturing facility in Norwood, MA, where the company manufactures its COVID-19 vaccine, Spikevax, and an experimental mRNA cancer vaccine being developed with Merck, according to an exclusive report obtained by Reuters via a Freedom of Information Act request.    According to Reuters, the Form 483 noted five separate observations, including that Moderna had released eight bat...